Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Cibus
CBUS
Cibus
Regulatory Risks And Concentration Will Delay Expansion But Allow Turnaround
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
15 Aug 25
Updated
15 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$1.60
11.9% undervalued
intrinsic discount
15 Aug
US$1.41
Loading
1Y
-81.6%
7D
-2.1%
Author's Valuation
US$1.6
11.9% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$1.6
11.9% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-292m
35m
2015
2017
2019
2021
2023
2025
2027
2028
Revenue US$15.5m
Earnings US$2.5m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
62.66%
Biotech revenue growth rate
13.11%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
11.92%
Calculation
US$2.47m
Earnings '28
x
65.28x
PE Ratio '28
=
US$160.99m
Market Cap '28
US$160.99m
Market Cap '28
/
71.78m
No. shares '28
=
US$2.24
Share Price '28
US$2.24
Share Price '28
Discounted to 2025 @ 11.92% p.a.
=
US$1.60
Fair Value '25
